| HS Code | 141228 |
| Product Name | Veratri Rhizoma Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Botanical Source | Dried rhizomes and roots of Veratrum nigrum L. |
| Active Constituents | Protoveratrine A, protoveratrine B, jervine, pseudojervine, rubijervine, veratridine, cevadine |
| Physical Form | Fine brownish to dark yellow-brown powder with a slight spicy odor |
| Assay | Total alkaloid content ≥ 40.0% w/w determined by HPLC |
| Particle Size Distribution | 100% passes through 80 mesh (≤180 µm); ≥95% passes through 120 mesh (≤125 µm) |
| Solubility | Sparingly soluble in water; freely soluble in ethanol, chloroform, diethyl ether, and dilute mineral acids |
| Loss On Drying | ≤ 5.0% w/w measured at 105°C for 3 hours |
| Total Ash | ≤ 8.0% w/w |
| Heavy Metals | Total heavy metals ≤ 20 ppm; lead ≤ 10 ppm; arsenic ≤ 5 ppm; cadmium ≤ 2 ppm; mercury ≤ 1 ppm |
| Microbial Limits | Total aerobic microbial count ≤ 1000 CFU/g; total yeast and mold ≤ 100 CFU/g; absence of Salmonella and Escherichia coli |
| Residual Solvents | Meets VICH/ICH limits; e.g., acetone ≤ 5000 ppm, ethanol ≤ 5000 ppm, methanol ≤ 3000 ppm |
| Dosage Form Compatibility | Suitable for incorporation into veterinary tablets, parenteral injections, capsules, powders, granules, oral premixes, and solutions |
| Shelf Life | 24 months when stored in unopened, properly sealed containers |
| Storage Conditions | Store in tightly closed, light-resistant containers in a cool, dry place below 30°C; keep away from moisture and strong light |
As an accredited Veratri Rhizoma Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in sealed, light-resistant, tamper-evident containers for stability and safety. Supplied in 1 kg, 5 kg, or 25 kg quantities. |
| Container Loading (20′ FCL) | Veratri Rhizoma API loaded in 20′ FCL, palletized drums/bags, secured with dunnage, ensuring safe, dry, compliant transport. |
| Shipping | Veratri Rhizoma Veterinary Grade API ships as a sealed, moisture-protected drum with tamper-evident seals, compliant with hazardous-material regulations. Store cool and dry, away from light. Deliver via temperature-controlled freight with clear labeling, documentation, and traceability for tablets, injections, capsules, powders, granules, premix, or solutions. |
| Storage | Store in tightly sealed, light-resistant containers in a cool, dry, well-ventilated area. Protect from moisture, direct sunlight, and extreme temperatures. Ensure container is properly labeled and kept away from incompatible substances, food, and animal feed. Maintain airtight seals after each use to preserve potency throughout the stated shelf life. |
| Shelf Life | Shelf life: 24 months from manufacture, when stored in sealed, original containers under controlled, dry conditions. |
Veratri Rhizoma Veterinary Grade API for tablet manufacturing is typically delivered as a dried total alkaloid fraction standardised by Ph. Eur. 2.2.29 HPLC-UV to protoveratrine A/B marker content, with a particle size distribution in the range d10 20–40 µm, d50 60–90 µm, d90 120–180 µm. Tablet cores containing this API are produced under the finished product monograph Ph. Eur. 0478 and are tested for content uniformity according to Ph. Eur. 2.9.40, mass uniformity according to Ph. Eur. 2.9.5, and release according to Ph. Eur. 2.9.3 paddle apparatus at 50 rpm in 900 mL 0.1 M HCl. In small-batch veterinary product development, the formulation addition ratio for direct compression is generally restricted to 0.20–1.00% w/w of the total core blend, corresponding to 0.50–2.50 mg per 250 mg tablet; above 1.00% w/w, alkaloid-rich agglomerates have been observed to segregate in the feed chute when relative humidity exceeds 60%, causing individual tablet potency deviations outside the Ph. Eur. 2.9.40 acceptance value 15. The preferred process route when the API is not pre-granulated is wet granulation in a high-shear granulator with main impeller speed 300–500 rpm, wet massing time 5–12 minutes, and binder addition of povidone K30 at 3.0–5.0% w/w dissolved in purified water. Granules are dried in a fluid-bed dryer at inlet air temperature 55–65°C to a final loss on drying of 1.5–2.5% w/w, then milled through a 0.8 mm screen. Lubrication with magnesium stearate at 0.5% w/w for 3–5 minutes is used before compression on a rotary tablet press with 10.0 mm flat-faced bevel-edge punches, main compression force 8–15 kN, and target hardness 60–90 N. A process conflict exists in disintegration design: croscarmellose sodium above 3.0% w/w accelerates disintegration below 5 minutes but risks an earlier dissolution inflection, which is undesirable for a narrow-therapeutic-index alkaloid fraction unless the dissolution specification includes a 15-minute control point. Terminal product types are immediate-release scored tablets for oral administration in 250 mg cores, packed in PVC/PVDC aluminium blisters with desiccant when the marketing authorization holder identifies moisture-sensitive stability data. Published product-specific data for this botanical configuration is limited, and the stated ranges represent conventional low-dose oral solid dosage development boundaries rather than a statutory monograph requirement.
| Parameter | Direct compression route | Wet granulation route |
|---|---|---|
| API addition ratio | 0.20–0.50% w/w | 0.50–1.00% w/w |
| Blend uniformity after terminal blending | ≤8% CV | ≤5% CV |
| Compression force | 10–18 kN | 8–15 kN |
| Tablet hardness range | 50–70 N | 60–90 N |
| Disintegration risk threshold | Croscarmellose sodium >2.0% w/w | Sodium starch glycolate >3.0% w/w |
In veterinary parenteral solution production, the low aqueous solubility of the non-protonated alkaloids and the presence of plant-derived lipophilic co-extractives that are not fully removed in the dried extract impose a measurable filtration constraint. The formulation addition ratio is held at 0.01–0.10 mg/mL total alkaloids expressed as protoveratrine A/B, with a co-solvent system containing 5.0–10.0% v/v ethanol or 0.5–2.0% v/v propylene glycol and the balance water for injection; direct aqueous compounding without co-solvent has been observed to produce filter blocking on 0.22 µm PVDF membranes within 20–40 minutes of recirculation, with differential pressure rising above 1.0 MPa. Sterile manufacturing is performed under Ph. Eur. 0520 Parenteral Preparations and EU GMP Annex 1 aseptic processing conditions; the finished product is tested for sterility by Ph. Eur. 2.6.1, bacterial endotoxins by Ph. Eur. 2.6.14, and sub-visible particulate matter by Ph. Eur. 2.9.19. The compounding sequence begins with the API dissolved in the ethanol or propylene glycol phase under high-shear rotor-stator mixing at 10,000 rpm for 15 minutes, followed by slow addition of water for injection with continuous nitrogen sparging; pH is adjusted to 4.0–5.0 with dilute hydrochloric acid to maintain the protonated alkaloid form and reduce hydrolysis. The bulk solution is passed through a 0.45 µm polypropylene pre-filter and then sterilising-grade 0.22 µm PVDF cartridge filter before aseptic filling into 10 mL Type I glass vials with butyl rubber stoppers. Terminal steam sterilisation is generally avoided for this alkaloid fraction because published stability data is limited and pilot-scale thermal challenge at 121°C for 15 minutes has shown unpredictable degradation of minor alkaloid peaks; the terminal product type is therefore an aseptic single-dose injection for veterinary use where the authorised indication and withdrawal period are established in the national dossier. An operational boundary: bulk hold time should not exceed 48 hours at 2–8°C unless stability data support longer storage.
For hard-shell capsule filling, the principal process conflict is low-dose blend segregation caused by the API particle size distribution and electrostatic charging at high-speed filling. The formulation addition ratio for encapsulated powder is 0.25–1.50% w/w of the fill mass, with a 250 mg fill weight delivering 0.625–3.75 mg total alkaloid per capsule; ratios below 0.25% w/w require a pre-blend with colloidal silicon dioxide at 0.5% w/w to reduce adhesion to contact parts. Capsule shells comply with Ph. Eur. 0016 for hard capsules, and the finished capsules are subjected to uniformity of dosage units by Ph. Eur. 2.9.40, with release testing by Ph. Eur. 2.9.3 where the product is an immediate-release oral veterinary medicinal product. Direct filling of raw API-spiked powder on a dosator or tamping-pin machine is not recommended for low-dose formulations because charge-induced agglomeration on the powder bed surface produces weight variability above 5% RSD after 15–20 minutes of continuous operation. The preferred route is dry granulation by roller compaction to a ribbon density of 1.0–1.2 g/cm³, milling to a granule fraction 180–710 µm, and blending in a bin blender at 12 rpm for 10–15 minutes. The final granule blend is filled on a tamping-pin capsule machine at 60,000–100,000 capsules/hour with dust extraction at the dosing station; capsule weight is checked every 15 minutes and fill weight limits are maintained within ±5% of target. The terminal product type is Size 1 or Size 0 hard gelatin or HPMC capsules, packaged in 100 mL HDPE bottles with silica gel desiccant and induction-sealed closure. An incompatibility boundary: if the API is combined with sodium starch glycolate above 2.0% w/w in a dry blend, rapid wicking can create localised wetting that initiates alkaloid hydrolysis during storage at 40°C/75% RH; therefore the disintegrant system should be evaluated under accelerated stability conditions before final capsule formulation lock.
An oral powder presentation imposes a containment hierarchy that is more severe than solid dosage forms because airborne alkaloid dust can reach industrial hygiene thresholds before visible dusting appears. The formulation addition ratio in a finished oral powder for reconstitution or in-feed top dressing is 0.05–0.50% w/w, with a 1 g single-dose sachet delivering 0.5–5.0 mg total alkaloid; for large-volume bulk powders intended for in-feed addition, the ratio is further reduced to 0.005–0.05% w/w to allow satisfactory dispersion in meal feed. Compliance for the manufacturing site includes Ph. Eur. 2.9.38 particle-size analysis by analytical sieving, Ph. Eur. 2.9.5 uniformity of mass for single-dose powders, EU GMP Part 4 for veterinary medicinal products, and national occupational exposure limits for active pharmaceutical ingredients. The blending process is performed under a downflow containment booth with local exhaust velocity 0.5 m/s; the API is first sifted through a 500 µm mesh stainless steel sieve and then geometrically diluted in a V-blender with an intensifier bar operating at 1,500 rpm for 3–5 minutes. Subsequent blending at 15 rpm for 20 minutes with a lactose monohydrate or mannitol carrier yields a coefficient of variation below 5% for the active marker. The final powder is filled into aluminium sachets at 25–30% RH to avoid moisture uptake; pre-drying of the API is required when incoming loss on drying exceeds 5.0% or when the production area relative humidity exceeds 60%. Terminal product types include single-dose oral powder sachets and bulk oral powder bottles with a 1.0 mL measuring spoon, intended for reconstitution or direct top dressing according to the veterinary prescription. The formulation boundary is that direct physical mixing of the raw API with a denser carrier such as calcium carbonate without geometric dilution leads to segregation and poor content uniformity; the blend must include a 1:5 intermediate pre-mix stage before final dilution.
For feed premix and granule manufacturing, Veratri Rhizoma alkaloid fraction is regulated as a medicated feed intermediate in the EU under Regulation (EU) 2019/4 and the veterinary medicinal product rules of Regulation (EU) 2019/6, with additional feed hygiene compliance under Regulation (EC) 183/2005 and FAMI-QS for specialty feed ingredients. The addition ratio for a Type A medicated article is 1.0–5.0% w/w API, which after dilution into final feed produces an active marker concentration of 0.002–0.01% w/w, equivalent to 20–100 g/tonne; the exact final feed inclusion rate is determined by the veterinary prescription and must not be altered without a stability-validated premix formula. Granulation is performed in a fluid-bed top-spray granulator with inlet air temperature 45–55°C, spray rate 20–40 g/min, and binder solution of hydroxypropyl methylcellulose at 2.0–4.0% w/w; the resulting granules are dried to 2.0–3.0% loss on drying and sieved to 150–850 µm. For premix production, the API is first de-agglomerated by mixing with colloidal silica at 1:5 in a high-shear mixer for 5 minutes, then incorporated into wheat midds or ground limestone at 1:10 in a ribbon mixer for 10 minutes, and finally diluted into the complete feed at 1:1000 with an additional 15 minutes mixing time. Homogeneity testing follows Regulation (EU) 2019/4 by sampling at least 10 points across the mixer discharge; the coefficient of variation for the marker alkaloid should be below 10% for the final feed and below 8% for the intermediate premix. Terminal product types are Type A medicated articles in 25 kg multi-wall paper bags with inner polyethylene liner, and final medicated meal or pelleted feed produced under veterinary prescription; if the feed is pelleted, the conditioning temperature must be kept below 70°C because pilot-scale data for this specific alkaloid fraction above that threshold is limited and thermal degradation cannot be excluded. The operational boundary is that the premix should not be stored above 25°C and 60% RH for more than 6 months unless real-time stability data are generated.
| Stage | API content | Carrier/phase | Mixing time | Target CV |
|---|---|---|---|---|
| 1 pre-blend | 20.0% w/w | colloidal silicon dioxide | 5 min | ≤8% |
| 2 intermediate premix | 2.0% w/w | wheat midds or ground limestone | 10 min | ≤8% |
| 3 final feed | 0.002% w/w | complete meal feed | 15 min | ≤10% |
Because the alkaloid fraction has limited aqueous solubility at neutral pH and is susceptible to hydrolysis in low-pH conditions without antioxidant control, solution manufacturing for oral drench or topical veterinary use requires a stabilised hydroalcoholic vehicle. The formulation addition ratio is 0.05–0.25% w/v total alkaloids, with the API extract dissolved at 0.5–1.0% w/v in a vehicle containing 10–20% v/v ethanol, 5–10% v/v propylene glycol, and purified water; sodium metabisulfite at 0.1% w/v is added as an antioxidant, and potassium sorbate at 0.2% w/v as a preservative. The finished solution is tested under Ph. Eur. 0672 for oral liquids or the corresponding veterinary liquid preparation monograph, with additional organoleptic and viscosity checks at release. The compounding sequence begins with the API extracted phase dissolved in ethanol under propeller stirring at 800–1,200 rpm for 20 minutes; the propylene glycol phase is added, then purified water is charged slowly to avoid precipitation. The pH is adjusted to 4.0–5.0 with citric acid or dilute sodium hydroxide, and the batch is recirculated through a 10 µm polypropylene bag filter followed by 0.45 µm cartridge filtration before filling. Terminal product types include 500 mL, 1 L, and 5 L amber PET or HDPE bottles with tamper-evident polypropylene caps for oral drench application or topical dip application according to the authorised label; contact with unlined aluminium caps is avoided because the acidic formulation can initiate corrosion at the closure neck. The operational boundary is that the finished solution should be protected from light and stored below 25°C; freeze-thaw cycling must be avoided because precipitation of minor alkaloid components may not fully redissolve without high-shear reworking. Published stability data for this specific botanical solution configuration is limited, and batch-specific photostability data should be collected before assigning a shelf life beyond 12 months.
Competitive Veratri Rhizoma Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Veratri Rhizoma Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as a standardised dry extract prepared from the dried rhizome and root of Veratrum nigrum L., with the total steroidal alkaloid fraction controlled by high-performance liquid chromatography. The article is designated by the product code VR-VET/API and is released in four grade codes that differ in particle-size distribution, residual moisture, endotoxin limit, and finished-dose suitability: VR-VET/API-T for tablets and hard capsules, VR-VET/API-P for powders, granules, and feed premixes, VR-VET/API-S for oral solutions and drenches, and VR-VET/API-I for injectable solutions or suspensions. It is supplied in sealed food-grade polyethylene liners within fibre drums, typically at a net fill of 25 kg, and is stored at ≤ 25 °C with low relative humidity. The article is not a retail preparation and is intended only for incorporation into registered veterinary finished dosage forms. Because veratridine-type alkaloids have a narrow therapeutic index and dose-related cardiovascular effects, batch selection must be based on the certificate of analysis, including assay, moisture, particle size, residual solvent, and microbiological data, rather than on visual appearance or sieve residue alone. The compendial identity of the source botanical is confirmed against the species monograph for Veratri Nigri Rhizoma in ChP 2020 where regional registration requires; other jurisdictions may require phytochemical equivalence data according to the relevant veterinary medicine guideline.
Grade selection begins with the downstream unit operation. The premix grade is specified with a particle-size distribution D90 ≤ 250 µm to permit homogeneous distribution in feed when diluted in a geometric series; the tablet and capsule grade is controlled to D90 ≤ 150 µm to support blend uniformity and compressibility. The solution grade is sieved to D90 ≤ 100 µm to accelerate wetting in aqueous vehicles. The injectable grade is air-jet milled to D90 ≤ 75 µm; where the finished form is a suspension rather than a solution, a narrower D90 of ≤ 10 µm is generally required to avoid capillary blockage and to satisfy USP <788> particulate matter criteria after final formulation.
Residual moisture is controlled by loss on drying at 105 °C according to USP <731> or Ph. Eur. 2.2.32. Tablet and injectable grades are limited to ≤ 3.0% and ≤ 2.0%, respectively; premix and solution grades are limited to ≤ 5.0%. Moisture above these limits increases particle cohesion, reduces flow through a rotary press, and can promote alkaloid hydrolysis during storage. The injectable grade additionally carries a bacterial endotoxin limit of < 0.5 EU/mg by the limulus amebocyte lysate test described in USP <85>; oral grades are not necessarily endotoxin-controlled unless the marketing authorisation specifically requires it. Microbial enumeration for non-sterile oral grades follows USP <61> and USP <62>, with total aerobic microbial count ≤ 1 × 10³ CFU/g, total yeast and mould count ≤ 1 × 10² CFU/g, and absence of Escherichia coli. The injectable grade is additionally tested for absence of Salmonella species and Pseudomonas aeruginosa.
Heavy metal and pesticide limits are established under USP <561>, Articles of Botanical Origin, when the destination market applies this chapter; typical acceptance values for arsenic, cadmium, lead, and mercury are not universal and must be stated on the certificate of analysis rather than assumed. Residual solvent presence depends on the extraction solvent. Ethanol-water extracts are controlled for ethanol by headspace gas chromatography under USP <467>, with a release limit commonly set at ≤ 0.5% for oral grades and ≤ 0.1% for injectable grades.
| Parameter | VR-VET/API-T | VR-VET/API-P | VR-VET/API-S | VR-VET/API-I |
|---|---|---|---|---|
| Particle size D90 | ≤ 150 µm | ≤ 250 µm | ≤ 100 µm | ≤ 75 µm; suspension ≤ 10 µm |
| Loss on drying | ≤ 3.0% | ≤ 5.0% | ≤ 5.0% | ≤ 2.0% |
| Bacterial endotoxin | Not specified | Not specified | Not specified | < 0.5 EU/mg |
| Total aerobic count | ≤ 10³ CFU/g | ≤ 10³ CFU/g | ≤ 10³ CFU/g | ≤ 10² CFU/g |
| E. coli | Absent in 1 g | Absent in 1 g | Absent in 1 g | Absent in 1 g |
Because the pharmacological activity resides in the steroidal alkaloid fraction, standardisation is performed against a marker set that may include veratridine, cevadine, and jervine, with total alkaloid content expressed as veratridine equivalents. The HPLC method is validated according to ICH Q2(R1); the acceptance range is defined in the registered specification and is generally narrower than the botanical monograph minimum to reduce batch-to-batch variability. Species authentication is critical: Veratrum nigrum L. and Veratrum album L. differ in alkaloid profile, and substitution with other Veratrum species can shift the ratio of veratridine to jervine and alter toxicity. The API is therefore identified by both macroscopic and microscopic examination and by high-performance thin-layer chromatography against an authenticated reference material. Extractable matter and total ash are tested by the general chapters of the relevant pharmacopoeia; acid-insoluble ash ≤ 2.0% is a common limit, but regional monographs may differ. A stable release pattern is not guaranteed by raw plant material. The extraction and drying stage is where total alkaloid content is adjusted by blending of validated intermediate batches or by addition of declared diluents such as maltodextrin. The diluent type is declared on the certificate of analysis because it affects tablet hardness, capsule fill weight, and solution clarity.
| Test parameter | Reference method / standard | Typical release criterion |
|---|---|---|
| Identification | Botanical monograph in ChP 2020; HPTLC | Positive match to authenticated reference |
| Assay, total steroidal alkaloids | HPLC-UV; validated per ICH Q2(R1) | Registered range based on label claim |
| Loss on drying | USP <731> | Grade-specific ≤ 2.0–5.0% |
| Microbial enumeration | USP <61>, USP <62> | Per grade; E. coli absent |
| Bacterial endotoxin | USP <85> | < 0.5 EU/mg injectable grade |
| Residual solvents | USP <467> | Ethanol ≤ 0.5% oral; ≤ 0.1% injectable |
| Heavy metals | USP <561> | As per certificate of analysis |
Tablets and capsules are usually manufactured by wet granulation rather than direct compression because the spray-dried extract contains a fine particle fraction that can segregate and cause weight variation. On a rotary tablet press fitted with 8 mm B-tooling, capping risk increases when the fines fraction below 75 µm exceeds 30%. A forced feeder is therefore used, and pre-compression force is maintained in the range of 2–4 kN. For hard capsules, the API is blended with lactose monohydrate and magnesium stearate; the magnesium stearate level is maintained at ≤ 1.0% because higher concentrations can delay dissolution and increase blend hydrophobicity. Granules for sachets and premixes are prepared by top-spray fluidised-bed granulation with an aqueous binder. The inlet air temperature is kept below 60 °C to limit thermal degradation of ester alkaloids. When the product is incorporated into feed premix, a three-step geometric dilution is used, and blend uniformity is tested by USP <905>, with acceptance limits for active substance content at ± 10% of label claim or according to the registered criterion. The carrier for premix should be selected for low moisture and neutral pH; ground corn cob or lactose carriers are acceptable if mineral oil is not used as a dust binder at levels that cause clumping. Cleaning validation in multi-product facilities is critical because the alkaloid fraction adheres to contact surfaces. Swab and rinse limits should be derived from toxicological permitted daily exposure for veratridine and confirmed under ICH Q7 good manufacturing practice.
Solutions and drenches are prepared by dissolving or dispersing the extract in purified water or a co-solvent system containing propylene glycol and water. Complete dissolution is not assumed because the lipophilic alkaloid fraction may require a pH below 4.0 or the presence of a solubiliser such as polysorbate 80. Compatibility of polysorbate with the extract must be confirmed by clarity and assay stability; precipitation can occur if the pH is raised too rapidly with strong alkali. For oral solutions, preservative efficacy is tested according to USP <51>. For injectable solutions, a non-aqueous vehicle may be necessary because the alkaloid fraction can be poorly soluble in aqueous systems at neutral pH. The API must be dissolved and filtered through a 0.22 µm polyvinylidene fluoride or polyethersulfone membrane before aseptic filling. The extract itself is not sterile, and terminal sterilisation by autoclaving at 121 °C for 15 min may degrade ester alkaloids. If terminal sterilisation is proposed, the heat load must be justified by pre- and post-sterilisation assay and impurity data. Container-closure integrity is tested under USP <1207> or equivalent. Depyrogenation of vials is conducted at 250 °C for 30 min when non-aqueous injectable vehicles are used.
Unlike powdered Veratrum nigrum root offered as an unprocessed botanical, the veterinary grade API is extracted to control total alkaloid content and reduce microbial burden. Crude powder can vary in alkaloid content by more than a factor of two across harvest seasons; the API is blended to a narrower release range and tested for residual solvents. It also differs from simple hydroalcoholic tinctures, which often lack a stabilised dry particle-size specification and are not validated for solid dose manufacturing. Compared with purified veratridine or other single alkaloid standards used as analytical tools, the API retains the multicomponent alkaloid fraction; this makes the product suitable for authorised veterinary preparations that rely on the natural fraction but also requires strict batch release because minor changes in alkaloid ratio can affect the cardiac and neurological response. The product is not directly substitutable for synthetic anthelmintics or electrolyte formulations; it is a botanical active substance with a narrow therapeutic window, and the dose must be established by the veterinary marketing authorisation. Published data comparing this exact grade with other Veratrum extracts in finished dose forms is limited; the applicant should generate comparative dissolution and stability data before substituting one material for another.
If the material is stored under relative humidity above 60% or the liner is left open, moisture uptake can exceed the direct compression limit. In such cases, vacuum drying at 40–45 °C and ≤ 10 kPa pressure is used to reduce moisture to ≤ 3.0% before tablet manufacture. Drying above 50 °C is avoided because ester alkaloids are susceptible to thermal degradation. The dried material should be passed through a 500 µm screen to break soft agglomerates. Pre-drying is not a substitute for a failed moisture specification; it is an in-house correction when the deviation is within the stability capability of the extract and is allowed by the marketing authorisation. Blend uniformity after re-drying must be verified because the fine fraction may segregate. The API is incompatible with strong oxidising agents, strong acids, and combinations with other cardioactive veterinary substances unless justified by the authorised formulation. Open handling of fine powder should be minimised; local exhaust ventilation is used because the dust may irritate the respiratory tract. The material is intended for use by licensed veterinary pharmaceutical manufacturers. It is not intended for food-producing animals unless the marketing authorisation includes withdrawal periods and residue data. Published production-scale data for this specific configuration is limited; each manufacturer must confirm filter compatibility, terminal sterilisation, and container-closure integrity under ICH Q1A or VICH GL3 stability protocols.
